SEC Form 8-K Summary
Registrant: Flora Growth Corp. (Nasdaq: FLGC), despite the request metadata identifying Zerostack Corp. The filing reports events occurring June 21–30, 2023 and was filed June 27, 2023 under Items 5.02, 7.01 and 9.01.
Business Context and Reporting Period
The filing concerns significant executive and board changes. It does not provide a financial reporting period, operating results or updated business-performance information.
Key Financial and Operating Metrics
- Revenue, profit, cash flow, margins, debt, liquidity and other financial metrics: the filing text does not provide clear values.
- Incoming CEO Clifford Starke’s existing consulting agreement provides for a base fee of $320,000, a discretionary annual bonus opportunity targeted at 80% of base fee and potential participation in equity and other incentive plans.
- Incoming CFO Dany Vaiman’s existing employment agreement provides for a base salary of $210,000, a discretionary annual bonus opportunity targeted at 50% of base salary and potential participation in equity and other incentive plans.
Material Changes Versus the Prior Comparable Period
- Hussein Rakine resigned as CEO effective June 25, 2023, while intending to remain on the Board. The filing states the resignation was not due to disagreement with the Company or Board.
- Elshad Garayev resigned as CFO effective June 25, 2023. He agreed to remain as an advisor for an additional month in exchange for one month of base salary. The filing states the resignation was not due to disagreement.
- Jessie Casner resigned as Chief Marketing Officer effective June 30, 2023. Vesting was accelerated for 5,102 restricted shares; remaining unvested restricted shares and options were forfeited.
- Jason Warnock resigned as Chief Commercial Officer effective June 30, 2023. Vesting was accelerated for 16,415 restricted shares; remaining unvested restricted shares and options were forfeited.
- Timothy Leslie resigned as a director and from the Audit Committee and Nominating and Corporate Governance Committee effective June 25, 2023. The Company plans to fill the Audit Committee vacancy within Nasdaq’s permitted cure period.
- Rakine agreed to forfeit 82,100 previously granted restricted common shares.
- Clifford Starke, previously President and a director, was appointed CEO effective June 25, 2023.
- Dany Vaiman, previously Senior Vice President of Finance, was appointed CFO effective June 25, 2023.
Guidance, Outlook, Risks and Unusual Items
- No revenue or earnings guidance, operating outlook or financial forecast was disclosed.
- The concentration of CEO, CFO and other senior-management departures may create transition and execution risks, although the filing does not characterize the departures as resulting from disagreements.
- Starke and Vaiman may be eligible for severance equal to one times their applicable base fee or salary upon qualifying termination, increasing to 1.5 times following or shortly before a change in control, subject to execution of a release and other agreement conditions.
- The separation agreements modify or waive certain non-compete restrictions. Starke and Vaiman remain subject to specified non-compete and non-solicitation provisions during their engagements and generally for 12 months afterward.
- The Board may consider future amendments to the consulting and employment agreements of Starke and Vaiman.
- The Company issued a related press release on June 27, 2023; the filing states that the Regulation FD information was furnished rather than filed for Exchange Act Section 18 purposes.
Investor Verification Checklist
- Confirm the registrant identity, because the supplied metadata says Zerostack Corp. while the filing identifies Flora Growth Corp.
- Review Exhibits 10.1–10.4 for the complete separation terms, releases, equity treatment and non-compete modifications.
- Verify whether the Audit Committee vacancy was filled within Nasdaq’s cure period and whether the Board’s committee composition remained compliant.
- Review future filings for amendments to the Starke consulting agreement and Vaiman employment agreement.
- Assess management-transition effects, severance obligations and any additional executive departures in subsequent filings.
- Review subsequent periodic reports for financial performance, liquidity, debt and updated operating guidance, none of which is provided in this 8-K.